4-Methylmorpholine → N-({4-[(2R,3R)-3-{[(2R)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-1-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-valine

HRID 1176068Notes

Reaction equation

HRID 1176068 reaction equation
[Si]([O:8][C@H:9]([C:42]1[CH:47]=[CH:46][C:45]([F:48])=[CH:44][CH:43]=1)[CH2:10][S:11][C@H:12]1[C:15](=[O:16])[N:14]([C:17]2[CH:22]=[CH:21][C:20]([C:23]#[C:24][CH2:25][NH:26][S:27]([CH3:30])(=[O:29])=[O:28])=[CH:19][CH:18]=2)[C@@H:13]1[C:31]1[CH:41]=[CH:40][C:34]([O:35][CH2:36][C:37](O)=[O:38])=[CH:33][CH:32]=1)(C(C)(C)C)(C)C.CN1CCOCC1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.Cl.[NH2:79][CH2:80][C:81]([NH:83][C@@H:84]([C:88]([OH:90])=[O:89])[CH:85]([CH3:87])[CH3:86])=[O:82].[Si](O[Si](C(C)(C)C)(C)C)(C(C)(C)C)(C)C>CN(C=O)C>[F:48][C:45]1[CH:46]=[CH:47][C:42]([C@@H:9]([OH:8])[CH2:10][S:11][C@H:12]2[C:15](=[O:16])[N:14]([C:17]3[CH:22]=[CH:21][C:20]([C:23]#[C:24][CH2:25][NH:26][S:27]([CH3:30])(=[O:29])=[O:28])=[CH:19][CH:18]=3)[C@@H:13]2[C:31]2[CH:41]=[CH:40][C:34]([O:35][CH2:36][C:37]([NH:79][CH2:80][C:81]([NH:83][C@@H:84]([C:88]([OH:90])=[O:89])[CH:85]([CH3:86])[CH3:87])=[O:82])=[O:38])=[CH:33][CH:32]=2)=[CH:43][CH:44]=1

Participants

7

Reactant 5

HCID 79724-MethylmorpholineHCID 590018TBDMS etherHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 68774413{4-[(2R,3R)-3-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(4-fluorophenyl)ethyl]thio}-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acidHCID 86628617Glycyl-D-valine hydrochloride

Product 1

HCID 68779487N-({4-[(2R,3R)-3-{[(2R)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-1-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-valine

Reagents, catalysts & solvents 1

HCID 6228DimethylformamideSolvent

Procedure

To a stirred solution of {4-[(2R,3R)-3-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(4-fluorophenyl)ethyl]thio}-1-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenoxy}acetic acid (19.4 mg, 0.027 mmol), and N-methylmorpholine (9 μl, 0.082 mmol) in DMF (1 ml, dry) was added. TBTU (12 mg, 0.037 mmol) and the reaction mixture was stirred at 30° C. for 1 hour. Glycyl-D-valine hydrochloride (8.0 mg, 0.038 mmol) was added and the reaction mixture was stirred for 1 hour. LC-MS showed the formation of the TBDMS-ether of the title compound, M/z: 868.68 (M−1). The reaction mixture was diluted with water and EtOAc. The solution was acidified with KHSO4 (2M) to pH ca 3. The phases were separated and the organic phase was concentrated. The residue was dissolved in acetic acid (1 ml). Water (100 μl) and LiCl (51.4 mg, 1.21 mmol) were added and the reaction mixture was stirred over the weekend. The acetic acid was co-evaporated with toluene. The residue was purified with preparative HPLC on a C8 column, UV 235/285 nm. A gradient from 20 to 80% MeCN in 0.1M NH4OAc buffer was used as eluent. The pure fractions were collected and most of the MeCN was removed under reduced pressure. The residue was diluted with water and DCM. It was acidified with KHSO4 (2M) to pH 3. The phases were separated and the organic phase was passed through a phase separator. The organic phase was concentrated and the residue was dissolved in MeCN and water. After lyophilisation, the title compound was obtained. H-NMR (500 MHz, DMSO-d6): 0.84 (d, 3H), 0.86 (d, 3H), 1.99-2.06 (m, 1H), 2.92 (d, 2H), 2.97 (s, 3H), 3.79-3.88 (m, 2H), 4.01 (d, 2H), 4.12-4.17 (m, 1H), 4.29 (d, 1H), 4.53 (s, 2H), 4.71 (t, 1H), 5.10 (d, 1H), 5.65 (bs, 1H), 6.99 (d, 2H), 7.08-7.13 (m, 2H), 7.20 (d, 2H), 7.30-7.40 (m, 6H), 7.58 (t, 1H), 8.02 (d, 1H), 8.24 (t, 1H), 12.65 (b, 1H). M/z: 753.52 (M−1).

Sources & evidence

ORD record
ord-80afba7bfcb8414294754d9c7df17f46
Source dataset
uspto-grants-2010_11
Patent number
US07842684B2

Reaction notes

Loading…